Events & Presentations | Apellis Pharmaceuticals, Inc.

Loading...

Investors & Media

Events & Presentations

Upcoming Events

Documents	Date
Second Quarter 2022 Earnings Presentation	August 8, 2022
Relationship Between Number of Intermediate/Large Drusen and Geographic Atrophy Lesion Growth Rate in the Sham Groups of the DERBY, OAKS, and FILLY Trials	July 16, 2022
Characterizing Real-World Functional Outcomes in Patients With Geographic Atrophy: An IRIS Registry Analysis	July 15, 2022
Retrospective Real-World Analysis of Patients with Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration Followed up for 3 Years	July 15, 2022
Safety of Intravitreal Pegcetacoplan for Geographic Atrophy (GA): 18-Month Results from the DERBY and OAKS trials	July 14, 2022
Assessment of Geographic Atrophy Lesion Progression in the Phase 3 DERBY and OAKS Trials	July 14, 2022
Characterization of Exudative AMD in the OAKS and DERBY Phase 3 Trials of Pegcetacoplan for Geographic Atrophy	June 10, 2022
Efficacy of Pegcetacoplan in Subgroups Defined by Distance from the Foveal Center Point in the Phase 3 OAKS and DERBY studies of Patients with Geographic Atrophy	June 10, 2022
Geographic Atrophy Lesion Growth in Pegcetacoplan-treated Study Eyes Versus Untreated Fellow Eyes in Patients with Bilateral GA in the OAKS, DERBY, and FILLY Trial	June 10, 2022
First Quarter 2022 Earnings Presentation	May 4, 2022
Efficacy of intravitreal pegcetacoplan in patients with geographic atrophy (GA): 18-month results from the phase 3 OAKS and DERBY studies	May 2, 2022
Impact of Baseline Imbalances on the Efficacy of Pegcetacoplan for the Treatment of Geographic Atrophy (GA): A Post-hoc Analysis of OAKS, DERBY, and FILLY	May 2, 2022
Results of a Delphi Consensus Study of Geographic Atrophy (GA) Diagnosis and Current Management	May 2, 2022
Apellis 18 Month Analysis of DERBY and OAKS Ph3 Studies	March 16, 2022
Fourth Quarter 2021 Earnings Presentation	February 28, 2022
40th Annual J.P. Morgan Healthcare Conference Presentation	January 10, 2022
Post Hoc Analysis of the Effect of Pegcetacoplan Treatment of Patients with Paroxysmal Nocturnal Hemoglobinuria and Baseline Hemoglobin Levels Greater Than 10 Grams per Deciliter	December 13, 2021
Efficacy and Safety of Pegcetacoplan Treatment in Complement-Inhibitor Naïve Patients with Paroxysmal Nocturnal Hemoglobinuria: Results from the Phase 3 PRINCE Study	December 13, 2021
Treatment of Geographic Atrophy Secondary to Age-Related Macular Degeneration With Pegcetacoplan: Updates on the Randomized Phase 3 DERBY and OAKS Trials	November 12, 2021
Third Quarter 2021 Earnings Presentation	November 8, 2021
Safety of intravitreal pegcetacoplan in geographic atrophy: results from the DERBY and OAKS trials	October 11, 2021
Efficacy of intravitreal pegcetacoplan in geographic atrophy: results from the DERBY and OAKS trials	October 11, 2021
Efficacy of intravitreal pegcetacoplan in geographic atrophy: results from the DERBY and OAKS trials	September 30, 2021
Safety of intravitreal pegcetacoplan in geographic atrophy: results from the DERBY and OAKS trials	September 30, 2021
Apellis DERBY and OAKS Phase 3 Top-Line Results Conference Call Presentation	September 9, 2021
Second Quarter 2021 Earnings Presentation	August 9, 2021
Apellis R&D Day Presentation	June 30, 2021
Apellis EMPAVELI FDA Approval Conference Call Presentation	May 17, 2021
First Quarter 2021 Earnings Presentation	April 28, 2021
Pegcetacoplan: Advancing the First Potential Treatment for Geographic Atrophy (GA) Presentation	January 28, 2021
39th Annual J.P. Morgan Healthcare Conference Presentation	January 12, 2021
Jefferies Virtual London Healthcare Conference Call Presentation	November 19, 2020
COVID-19 Study Updates	October 15, 2020
PEGASUS Phase 3 Top-Line Results Conference Call Presentation	January 7, 2020

Past Events

Print Page Email Alerts RSS Feeds Contact IR

© Apellis Pharmaceuticals 2022. All rights reserved.

This website is intended for residents of the U.S.